| Abstract | Cilj istraživanja: Cilj ovog istraživanja bio je usporediti serumske koncentracije Urotenzina II u bolesnika s Crohnovom bolešću i kontrolnih ispitanika.
Ispitanici i postupci: U istraživanje je bilo uključeno 30 bolesnika s Crohnovom bolešću i 30 zdravih kontrolnih ispitanika. Svim ispitanicima je određena tjelesna masa, tjelesna visina i krvni tlak. Nadalje, svim ispitanicima su uzeti uzorci krvi na tašte nakon 12 satnog posta.
Rezultati: Pronađene su statistički značajno više razine Urotenzina II u bolesnika s Crohnovom bolešću u odnosu na kontrolnu skupinu (7,32 ± 1,67 ng/mL vs 1,97 ± 0,87 ng/mL, P<0.001). CD skupina je također imala i statistički značajno višu razinu hsCRP-a (3,5 ± 2,4 mg/L vs 1,1 ± 0,8 mg/L, P<0,001) dok je kontrolna skupina imala statistički značajno višu razinu hemoglobina (140,2 ± 14,9 g/L vs 149,9 ± 11,7 g/L, P<0,007) i ureje (4,7 ± 1,5 mmol/L vs 5,9 vs ± 1,9 mmol/L, P<0,013). Nadalje, u bolesnika s Crohnovom bolešću pronađena je statistički značajna pozitivna korelacija između koncentracije urotenzina II te sistoličkog krvnog tlaka (r=0,598, P<0,001), dijastoličkog krvnog tlaka (r=0,598, P<0,002), SES-CD-a (r=0,451, P<0.031) i hsCRP (r=0,774, P<0,001). Multipla linearna regresijska analiza neovisnih prediktora serumskih koncentracija Urotenzina II pokazala je povezanost s hsCRP-om (β=0,920, SE=0.124, P<0.001), indeksom tjelesne mase (β=-0.319, SE=0.095, P<0,001), spolom (β=-1,319, SE=0,575, P<0.025) i dobi (β=0.044, SE=0.021, P<0.040).
Zaključci: Ovo istraživanje je pokazalo da je serumska koncentracija Urotenzina II značajno viša u bolesnika s Crohnovom bolešću u odnosu na kontrolnu skupinu što upućuje na to da Urotenzin II potencijalno sudjeluje u patogenezi i patofiziologiji ove bolesti. Nadalje, pokazano je da su serumske koncentracije Urotenzina II u značajnoj pozitivnoj korelaciji s hsCRP-om, aktivnošću Crohnove bolesti te sistoličkim i dijastoličkim tlakom. |
| Abstract (english) | Aim of the study: The aim of this study was to compare the serum concentrations of Urotensin II in Crohn's disease patients and control subjects.
Respondents and procedures: The study included 30 patients with Crohn's disease and 30 healthy control subjects. All subjects were determined for body weight, body height and blood pressure. Furthermore, fasting blood samples were taken from all subjects after a 12-hour fast.
Results: Statistically significantly higher levels of Urotensin II were found in patients with Crohn's disease compared to the control group (7.32 ± 1.67 ng / mL vs 1.97 ± 0.87 ng / mL, P <0.001). The CD group also had a statistically significantly higher level of hsCRP (3.5 ± 2.4 mg / L vs 1.1 ± 0.8 mg / L, P <0.001) while the control group had a statistically significantly higher level of hemoglobin (140.2 ± 14.9 g / L vs 149.9 ± 11.7 g / L, P <0.007) and urea (4.7 ± 1.5 mmol / L vs 5.9 vs ± 1.9 mmol) / L, P <0.013). Furthermore, in patients with Crohn's disease, a statistically significant positive correlation was found between urotensin II concentration and systolic blood pressure (r = 0.598, P <0.001), diastolic blood pressure (r = 0.598, P <0.002), SES-CD ( r = 0.451, P <0.031) and hsCRP (r = 0.774, P <0.001). Multiple linear regression analysis of independent predictors of serum Urotensin II concentrations showed an association with hsCRP (β = 0,920, SE = 0.124, P <0.001), body mass index (β = -0.319, SE = 0.095, P <0.001), sex (β = -1.319, SE = 0.575, P <0.025) and age (β = 0.044, SE = 0.021, P <0.040).
Conclusion: In this study, we showed that the serum concentration of Urotensin II was significantly higher in patients with Crohn's disease compared to the control group, which suggests that Urotensin II potentially participates in the pathogenesis and pathophysiology of this disease. |
